Proximal Ventures, a San Francisco-based early-stage venture capital firm focused on artificial intelligence and life sciences, has closed its inaugural fund at $27.5 million, exceeding its original $25 million fundraising target. The fund will invest in pre-seed and seed-stage companies developing AI-native software and infrastructure across pharmaceutical research, clinical development, manufacturing, and commercialization.
Founded in 2026 by Sahir Raoof, Proximal Ventures is pursuing a specialized investment strategy centered on the pharmaceutical value chain, supporting emerging technologies from molecular discovery through the delivery of medicines to patients.
The fund is backed by strategic partners including Domino Lane, SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and PagsGroup. Individual investors include Nan Li and Zavain Dar, co-founders of venture capital firm Dimension.
Proximal’s investment thesis reflects the growing application of AI across life sciences, where advances in computational research are creating opportunities to improve drug discovery and development.
While much of the industry’s attention has focused on using AI to identify new therapeutic candidates, Proximal sees additional opportunities in the processes required to develop, manufacture, approve, and commercialize medicines.
These activities represent a substantial portion of pharmaceutical industry spending and involve complex regulatory, scientific, and operational requirements.
The firm intends to support startups developing technologies capable of improving efficiency, reducing costs, and accelerating workflows throughout these processes.
Potential investment areas include computational drug discovery, clinical trial infrastructure, pharmaceutical manufacturing systems, and technologies supporting market access and commercialization.
Proximal believes AI-native companies can address operational challenges that have historically received less venture capital attention than drug discovery platforms.
Supporting Founders From Company Formation
Proximal differentiates its investment approach through direct involvement with founders during the earliest stages of company development.
The firm works with entrepreneurs to validate business ideas, develop go-to-market strategies, and establish relationships with prospective pharmaceutical customers.
In some cases, Proximal begins supporting founders before their companies have been formally incorporated.
This approach is intended to help startups develop products based on actual requirements within the pharmaceutical industry.
Life sciences technology companies frequently face challenges involving lengthy sales cycles, regulatory requirements, integration with existing systems, and the need to demonstrate value to specialized customers.
Proximal aims to address these issues by connecting founders with industry executives, technology partners, and potential design customers.
Its advisory network includes Amy Abernethy, Co-Founder of Highlander Health and former Principal Deputy Commissioner of the U.S. Food and Drug Administration.
The network also includes Kim Branson, Chief AI Officer at GSK, along with other senior executives from pharmaceutical and technology companies.
These relationships provide portfolio companies with access to expertise involving regulation, pharmaceutical operations, and enterprise technology adoption.
Investment Experience And Early Portfolio Development
Raoof brings more than a decade of experience working with and investing in life sciences businesses.
Before establishing Proximal, he served as the first commercial hire and Vice President of Business Development at Iterative Health.
He also developed biopharmaceutical research partnerships at Flatiron Health, which was acquired by Roche.
Earlier in his career, Raoof worked at J.P. Morgan, covering biotechnology companies and outsourced pharmaceutical services.
Most recently, he led technology-enabled biotechnology and pharmaceutical technology investments at SignalFire.
His background combines pharmaceutical industry knowledge with experience evaluating emerging technology businesses.
Proximal has already begun deploying capital from Fund I and has participated in competitive financing rounds alongside established multistage investment firms.
One portfolio company is Chronicle Bio, whose leadership highlighted Proximal’s understanding of healthcare data and its ability to provide strategic guidance.
The firm intends to build on these early investments by identifying additional founders developing AI-powered infrastructure for life sciences.
The strategy emphasizes businesses that can improve how pharmaceutical companies conduct research, execute clinical development programs, manage manufacturing, and bring treatments to market.
With $27.5 million in committed capital, Proximal Ventures is positioning itself as a specialized investor in technologies designed to modernize the pharmaceutical industry.
The firm’s combination of early-stage investment capital, hands-on commercial support, and industry relationships is intended to help founders develop scalable businesses while improving the efficiency of bringing new medicines to patients.
KEY QUOTES
“I am excited about AI’s potential to discover better medicines and then transform every step of bringing them to patients. Proximal is supporting founders across that entire journey, from computational drug discovery through development and commercialization. Some of the greatest opportunities lie in areas that have historically attracted less venture investment, and we see tremendous potential to build important companies throughout the value chain.”
Sahir Raoof, Founder And Managing Partner Of Proximal Ventures
“Proximal brings a rare combination of deep industry relationships and a real understanding of our data ecosystem. The expertise and advisory role its network plays is shaping the way we think about eliminating the burden of complex chronic disease.”
Rohit Gupta, Co-Founder And CEO Of Chronicle Bio
“Much of what determines whether a drug succeeds happens long after it’s discovered, in the trials, manufacturing, commercial, and regulatory work that I have seen few investors understand in totality. That rare combination is driving Proximal, and ultimately the companies it backs, to change how we see life sciences.”
Jim Lim, Managing Partner Of Domino Lane

